Saturday, October 31, 2026

Rivian Scraps 2027 Profit Goal, Joins Global Race for Autonomous Vehicle Dominance

Rivian Automotive has abandoned its 2027 profitability target to fund autonomous vehicle development, partnering with Uber Technologies in a strategic shift. The decision mirrors choices facing EV manufacturers worldwide as Chinese competitors like BYD and Xpeng advance autonomous capabilities while Western automakers balance short-term returns against AI mobility investments.

LM Salvado
LM Salvado

March 24, 2026

Rivian Scraps 2027 Profit Goal, Joins Global Race for Autonomous Vehicle Dominance
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Rivian Automotive withdrew its 2027 profitability target to fund autonomous vehicle development, joining a global competitive landscape where Chinese manufacturers already deploy advanced self-driving systems. The American EV maker is reallocating capital to autonomous technology infrastructure through a robotaxi partnership with Uber Technologies.

Uber's strategic investment in Rivian marks a return to autonomous vehicles after the ride-hailing giant sold its Uber ATG self-driving unit in 2020. That sale highlighted the capital intensity of in-house autonomous development, a challenge now facing automakers across North America, Europe, and Asia as they compete with China's rapidly advancing autonomous vehicle ecosystem.

Rivian's R2 vehicle platform may serve as the foundation for the Uber robotaxi collaboration, providing a deployment path through Uber's global ride-hailing network spanning 70 countries. The partnership structure differs from approaches in China, where companies like Baidu operate independent robotaxi services, and Europe, where regulatory frameworks remain fragmented across member states.

The profitability delay reflects strategic divergence in the global EV industry. Chinese manufacturers like BYD and Xpeng are already integrating advanced driver assistance systems while maintaining profitability through scale and vertical integration. Western automakers face pressure to match autonomous capabilities without China's manufacturing cost advantages or domestic market protection.

Rivian's choice prioritizes long-term positioning in AI-enabled mobility over near-term earnings, betting that autonomous technology will reshape transportation markets globally. The strategy carries risk as capital-intensive development timelines extend and competition intensifies from established automakers, technology companies, and well-funded Chinese competitors entering international markets.

Note: This article was generated from analytical data. Proper source citations cannot be included without access to original source documents.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com